Balancing benefits and harms of treatments for acute bipolar depression

Terence A. Ketter, Shefali Miller, Bernardo Dell'Osso, Joseph R. Calabrese, Mark A. Frye, Leslie Citrome

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments.

Methods Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm (NNH) for selected side effects for older and newer acute bipolar depression treatments.

Results The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy in bipolar depression has not been consistently demonstrated in randomized controlled trials.

Limitations NNT and NNH are categorical metrics; only selected NNHs were assessed; limited generalizability of efficacy (versus effectiveness) studies.

Conclusion For acute bipolar depression, older approved treatments may have utility in high-urgency situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly approved lurasidone may ultimately prove useful in diverse situations. New drug development needs to focus on not only efficacy but also on tolerability.

Original languageEnglish
Pages (from-to)S24-S33
JournalJournal of Affective Disorders
Volume169
Issue numberS1
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Numbers Needed To Treat
Bipolar Disorder
Antidepressive Agents
Therapeutics
Psychomotor Agitation
Nausea
Weight Gain
Meta-Analysis
Randomized Controlled Trials
Placebos

Keywords

  • Antidepressants
  • Antidepressants
  • Antipsychotics
  • Armodafinil
  • Bipolar depression
  • Bipolar disorder
  • Lamotrigine
  • Lurasidone
  • Mood stabilizers
  • Number needed to harm
  • Number needed to treat
  • Olanzapine plus fluoxetine
  • Quetiapine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Medicine(all)

Cite this

Balancing benefits and harms of treatments for acute bipolar depression. / Ketter, Terence A.; Miller, Shefali; Dell'Osso, Bernardo; Calabrese, Joseph R.; Frye, Mark A.; Citrome, Leslie.

In: Journal of Affective Disorders, Vol. 169, No. S1, 01.12.2014, p. S24-S33.

Research output: Contribution to journalArticle

Ketter, Terence A. ; Miller, Shefali ; Dell'Osso, Bernardo ; Calabrese, Joseph R. ; Frye, Mark A. ; Citrome, Leslie. / Balancing benefits and harms of treatments for acute bipolar depression. In: Journal of Affective Disorders. 2014 ; Vol. 169, No. S1. pp. S24-S33.
@article{f15135730ae54263add0795c6d637379,
title = "Balancing benefits and harms of treatments for acute bipolar depression",
abstract = "Background Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments.Methods Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm (NNH) for selected side effects for older and newer acute bipolar depression treatments.Results The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy in bipolar depression has not been consistently demonstrated in randomized controlled trials.Limitations NNT and NNH are categorical metrics; only selected NNHs were assessed; limited generalizability of efficacy (versus effectiveness) studies.Conclusion For acute bipolar depression, older approved treatments may have utility in high-urgency situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly approved lurasidone may ultimately prove useful in diverse situations. New drug development needs to focus on not only efficacy but also on tolerability.",
keywords = "Antidepressants, Antidepressants, Antipsychotics, Armodafinil, Bipolar depression, Bipolar disorder, Lamotrigine, Lurasidone, Mood stabilizers, Number needed to harm, Number needed to treat, Olanzapine plus fluoxetine, Quetiapine",
author = "Ketter, {Terence A.} and Shefali Miller and Bernardo Dell'Osso and Calabrese, {Joseph R.} and Frye, {Mark A.} and Leslie Citrome",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/S0165-0327(14)70006-0",
language = "English",
volume = "169",
pages = "S24--S33",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "S1",

}

TY - JOUR

T1 - Balancing benefits and harms of treatments for acute bipolar depression

AU - Ketter, Terence A.

AU - Miller, Shefali

AU - Dell'Osso, Bernardo

AU - Calabrese, Joseph R.

AU - Frye, Mark A.

AU - Citrome, Leslie

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments.Methods Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm (NNH) for selected side effects for older and newer acute bipolar depression treatments.Results The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy in bipolar depression has not been consistently demonstrated in randomized controlled trials.Limitations NNT and NNH are categorical metrics; only selected NNHs were assessed; limited generalizability of efficacy (versus effectiveness) studies.Conclusion For acute bipolar depression, older approved treatments may have utility in high-urgency situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly approved lurasidone may ultimately prove useful in diverse situations. New drug development needs to focus on not only efficacy but also on tolerability.

AB - Background Bipolar depression is more pervasive than mania, but has fewer evidence-based treatments.Methods Using data from multicenter, randomized, double-blind, placebo-controlled trials and meta-analyses, we assessed the number needed to treat (NNT) for response and the number needed to harm (NNH) for selected side effects for older and newer acute bipolar depression treatments.Results The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5). Commonly used unapproved agents (lamotrigine monotherapy and adjunctive antidepressants) tended to be well-tolerated (with double-digit NNHs), although this advantage was at the cost of inadequate efficacy (response NNT=12 for lamotrigine, NNT=29 for antidepressants). In contrast, the newly approved agent lurasidone was not only efficacious (response NNT=5 for monotherapy, NNT=7 as adjunctive therapy), but also had enhanced tolerability (NNH=15 for akathisia [monotherapy], NNH=16 for nausea [adjunctive]). Although adjunctive armodafinil appeared well tolerated, its efficacy in bipolar depression has not been consistently demonstrated in randomized controlled trials.Limitations NNT and NNH are categorical metrics; only selected NNHs were assessed; limited generalizability of efficacy (versus effectiveness) studies.Conclusion For acute bipolar depression, older approved treatments may have utility in high-urgency situations, whereas lamotrigine and antidepressants may have utility in low-urgency situations. Newly approved lurasidone may ultimately prove useful in diverse situations. New drug development needs to focus on not only efficacy but also on tolerability.

KW - Antidepressants

KW - Antidepressants

KW - Antipsychotics

KW - Armodafinil

KW - Bipolar depression

KW - Bipolar disorder

KW - Lamotrigine

KW - Lurasidone

KW - Mood stabilizers

KW - Number needed to harm

KW - Number needed to treat

KW - Olanzapine plus fluoxetine

KW - Quetiapine

UR - http://www.scopus.com/inward/record.url?scp=84919668795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919668795&partnerID=8YFLogxK

U2 - 10.1016/S0165-0327(14)70006-0

DO - 10.1016/S0165-0327(14)70006-0

M3 - Article

VL - 169

SP - S24-S33

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - S1

ER -